SUPERIOR BACTERIAL VACCINES

based on a novel technology platform 

targeting antimicrobial resistant bacterial infections

"Our core mission is to contribute to global health by providing new innovative vaccines overcoming the urgent medical problem of antimicrobial resistance. Utilizing our proprietary technology platform, we enable production of safe and superior immunogenic toxoid antigens for highly needed vaccines to disarm specific pathogenic bacteria without the need for non-specific antimicrobial treatment."

Proxi Biotech, 2023

ANTIMICROBIAL RESISTANCE (AMR)

One of the world's most pressing medical problems

1.2M

Die each year from AMR, and the number is increasing by the day

10M

Deaths from AMR each year by 2050, which is a bigger killer than cancer

€ 100 Trillion

Financial burden from AMR, reducing global economic output by up to 3.5%

WHAT WE DO

Proxi Biotech is an innovative biopharmaceutical company with a focus on utilizing its proprietary and patent-pending BACTOVAC technology platform for the development of novel, safe and highly immunogenic and efficacious vaccines against unmet need AMR infections.


Our BACTOVAC platform overcomes main barriers of traditional vaccine developing technologies, and fast-tracks the development of new and highly needed vaccines in widely untapped markets for the benefit of people and society. 

Toxoid vaccines are the best weapon against AMR


Many unmet need infections can be prevented with effective vaccines

Effective vaccines will reduce AMR and the extensive use of antibiotics

Current technologies for toxoid vaccine production are suboptimal


VACCINE PROGRAMS

TARGETING HIGH-PRIORITY UNMET NEEDS

All vaccines are developed by leveraging from the strength and versatility of our BACTOVAC platform

CDIFFVAC: A superior and broad-protective toxoid vaccine for prevention and treatment of Clostridium difficile infection 

UTIVAC: A multi-faceted nasal vaccine for prevention and treatment of urinary tract infection caused by UPEC 

PTVAC: A more immunogenic and longer-lasting toxoid nasal vaccine for prevention and treatment of whooping cough

FOLLOW OUR PROJECTS